The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 13F

FORM 13F INFORMATION TABLE

OMB APPROVAL
OMB Number: 3235-0006
Estimated average burden
hours per response: 23.8

COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8
VALUE SHRS OR SH/ PUT/ INVESTMENT OTHER VOTING AUTHORITY
NAME OF ISSUER TITLE OF CLASS CUSIP (x$1000) PRN AMT PRN CALL DISCRETION MANAGER SOLE SHARED NONE
Altimmune, Inc. Common 02155H101 8 7,000 SH   SOLE   7,000 0 0
Aratana Therapeutics Inc. Common 03874P101 1,103 250,000 SH   SOLE   250,000 0 0
Chiasma, Inc. Common 16706W102 8,604 5,736,296 SH   SOLE   5,736,296 0 0
Conatus Pharmaceuticals, Inc. Common 20600T108 14,468 2,464,807 SH   SOLE   2,464,807 0 0
Endologix, Inc. Common 29266S106 4,744 1,121,447 SH   SOLE   1,121,447 0 0
Proteon Therapeutics, Inc. Common 74371L109 2,458 983,381 SH   SOLE   983,381 0 0
Radius Health, Inc. Common 750469207 143,736 3,999,343 SH   SOLE   3,999,343 0 0
Rhythm Pharmaceuticals, Inc. Common 76243J105 53,658 2,696,392 SH   SOLE   2,696,392 0 0
Syndax Pharmaceuticals, Inc. Common 87164F105 30,860 2,168,691 SH   SOLE   2,168,691 0 0